Tags

Type your tag names separated by a space and hit enter

Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs.
Cancer 2003; 97(7):1732-6C

Abstract

BACKGROUND

Nonsteroidal antiinflammatory drugs (NSAIDs) inhibit the development of lung tumors in experimental animals. To the authors' knowledge there are little data regarding whether regular use of NSAIDs reduces the risk of developing lung carcinoma in humans.

METHODS

The association between lung carcinoma risk and regular use of NSAIDs, including aspirin, was evaluated in a hospital-based case-control study of 1038 patients and 1002 controls.

RESULTS

The relative risk estimate of lung carcinoma associated with using NSAIDs 3 times a week or more for 1 or more years demonstrated an odds ratio (OR) of 0.68 (95% confidence interval [95% CI], 0.53-0.89). Results were similar when separated by lung histologic type. The association varied by smoking status. The OR was 1.28 (95% CI, 0.73-2.25) in never-smokers and 0.60 (95% CI 0.45-0.80) in ever-smokers. The smoking-specific risk estimates for aspirin were similar to those for all NSAIDs.

CONCLUSIONS

The results of the current study suggest a possible chemoprotective benefit with the use of NSAIDs among individuals who are former or current smokers.

Authors+Show Affiliations

American Health Foundation, Valhalla, New York 10595, USA. jmuscat@ahf.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

12655530

Citation

Muscat, Joshua E., et al. "Risk of Lung Carcinoma Among Users of Nonsteroidal Antiinflammatory Drugs." Cancer, vol. 97, no. 7, 2003, pp. 1732-6.
Muscat JE, Chen SQ, Richie JP, et al. Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs. Cancer. 2003;97(7):1732-6.
Muscat, J. E., Chen, S. Q., Richie, J. P., Altorki, N. K., Citron, M., Olson, S., ... Stellman, S. D. (2003). Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs. Cancer, 97(7), pp. 1732-6.
Muscat JE, et al. Risk of Lung Carcinoma Among Users of Nonsteroidal Antiinflammatory Drugs. Cancer. 2003 Apr 1;97(7):1732-6. PubMed PMID: 12655530.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs. AU - Muscat,Joshua E, AU - Chen,Shu-Quan, AU - Richie,John P,Jr AU - Altorki,Nasser K, AU - Citron,Marc, AU - Olson,Sara, AU - Neugut,Alfred I, AU - Stellman,Steven D, PY - 2003/3/26/pubmed PY - 2003/4/17/medline PY - 2003/3/26/entrez SP - 1732 EP - 6 JF - Cancer JO - Cancer VL - 97 IS - 7 N2 - BACKGROUND: Nonsteroidal antiinflammatory drugs (NSAIDs) inhibit the development of lung tumors in experimental animals. To the authors' knowledge there are little data regarding whether regular use of NSAIDs reduces the risk of developing lung carcinoma in humans. METHODS: The association between lung carcinoma risk and regular use of NSAIDs, including aspirin, was evaluated in a hospital-based case-control study of 1038 patients and 1002 controls. RESULTS: The relative risk estimate of lung carcinoma associated with using NSAIDs 3 times a week or more for 1 or more years demonstrated an odds ratio (OR) of 0.68 (95% confidence interval [95% CI], 0.53-0.89). Results were similar when separated by lung histologic type. The association varied by smoking status. The OR was 1.28 (95% CI, 0.73-2.25) in never-smokers and 0.60 (95% CI 0.45-0.80) in ever-smokers. The smoking-specific risk estimates for aspirin were similar to those for all NSAIDs. CONCLUSIONS: The results of the current study suggest a possible chemoprotective benefit with the use of NSAIDs among individuals who are former or current smokers. SN - 0008-543X UR - https://www.unboundmedicine.com/medline/citation/12655530/Risk_of_lung_carcinoma_among_users_of_nonsteroidal_antiinflammatory_drugs_ L2 - https://doi.org/10.1002/cncr.11242 DB - PRIME DP - Unbound Medicine ER -